{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:23:03Z","timestamp":1785414183199,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Spironolactone, a potassium-sparing diuretic, is used to treat hypertension, heart failure, and certain hyperandrogenic disorders. Its use during pregnancy is not recommended due to the risk of feminizing male fetuses, primarily because of its antiandrogenic activity. However, human data remain scarce and largely inconclusive. Here, we present the first case of a 25-year-old pregnant woman, at 16 weeks of gestation, who was inadvertently exposed to spironolactone (240\u00a0mg\/day) for 1\u00a0week due to a pharmacy dispensing error. The patient subsequently delivered a healthy male infant with normal genitalia at 38\u00a0weeks of gestation following vaginal delivery. Current follow-up shows that the infant is healthy and developing normally. This article summarizes the potential causes of spironolactone-induced anomalous genital development and explores the safety of new-generation mineralocorticoid receptor antagonists (MRAs) during pregnancy. The mechanisms behind spironolactone-induced anomalous genital development in male fetuses have not been fully elucidated. Spironolactone competes with dihydrotestosterone for binding to androgen receptors and inhibits enzymes involved in androgen biosynthesis, which may partly explain its antiandrogenic effects. Recent advancements in MRAs have led to the development of compounds with higher selectivity for the mineralocorticoid receptor, thereby reducing the incidence of antiandrogen side effects. These new-generation MRAs may be effective alternatives during pregnancy, but more data are needed to establish their safety in pregnant women. This case contributes to the limited but growing body of literature on the safety profile of spironolactone in pregnancy, providing insights into its effects during a critical period of fetal development.<\/jats:p>","DOI":"10.3389\/fphar.2024.1404251","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:36:57Z","timestamp":1721882217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report: A pregnant woman accidental treated with spironolactone in mid-gestation"],"prefix":"10.3389","volume":"15","author":[{"given":"Nianying","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jaad.2018.08.062","article-title":"Androgens in women: androgen-mediated skin disease and patient evaluation","volume":"80","author":"Bienenfeld","year":"2019","journal-title":"J. Am. Acad. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0303-7207(74)90012-4","article-title":"Mode of spironolactone anti-androgenic action: inhibition of androstanolone binding to rat prostate androgen receptor","volume":"2","author":"Bonne","year":"1974","journal-title":"Mol. Cell. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2020.03.087","article-title":"Spironolactone for treatment of female pattern hair loss","volume":"83","author":"Burns","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"bvac003","DOI":"10.1210\/jendso\/bvac003","article-title":"Female adult acne and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee","volume":"6","author":"Carmina","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.7326\/0003-4819-79-2-198","article-title":"Estrogen-androgen imbalance in hepatic cirrhosis. Studies in 13 male patients","volume":"79","author":"Chopra","year":"1973","journal-title":"Ann. Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08998280.2004.11927973","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc. (Bayl Univ. Med. Cent)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00404-009-0994-3","article-title":"Gitelman syndrome during pregnancy: a therapeutic challenge","volume":"280","author":"de Arriba","year":"2009","journal-title":"Arch. Gynecol. Obstet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/CRD.0000000000000548","article-title":"Finerenone: efficacy of a new nonsteroidal mineralocorticoid receptor antagonist in treatment of patients with chronic kidney disease and type 2 diabetes","volume":"32","author":"Dey","year":"2024","journal-title":"Cardiol. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1345\/aph.18175","article-title":"Pregnancy outcome of women exposed to pinaverium due to a dispensing error","volume":"33","author":"Einarson","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"B12","first-page":"131","article-title":"Finerenone (Kerendia) for chronic kidney disease","volume":"63","year":"2021","journal-title":"Med. Lett. Drugs Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11154-022-09729-6","article-title":"Primary aldosteronism in pregnancy","volume":"24","author":"Forestiero","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0016-5085(87)90428-8","article-title":"Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver","volume":"93","author":"Francavilla","year":"1987","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s11096-016-0267-8","article-title":"Lack of pharmacist-physician communication associated with nimesulide-induced oligohydramnios during pregnancy","volume":"38","author":"Grincevi\u010dien\u0117","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/0002-9378(95)90549-9","article-title":"Spironolactone therapy during human pregnancy","volume":"172","author":"Groves","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1530\/acta.0.0950540","article-title":"Disturbances in sexual differentiation of rat foetuses following spironolactone treatment","volume":"95","author":"Hecker","year":"1980","journal-title":"Acta Endocrinol. (Copenh)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2021.07.048","article-title":"Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review","volume":"86","author":"James","year":"2022","journal-title":"J. Am. Acad. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1095\/biolreprod32.5.1051","article-title":"Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone","volume":"32","author":"Jaussan","year":"1985","journal-title":"Biol. Reprod."},{"key":"B20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/b978-1-4831-9825-5.50017-8","article-title":"Problems of fetal endocrinology: the adrenal glands","volume":"22","author":"Jost","year":"1966","journal-title":"Recent Prog. Horm. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertens. (Dallas, Tex 1979)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.kint.2020.10.035","article-title":"Diagnosis and management of bartter syndrome: executive summary of the consensus and recommendations from the European rare kidney disease reference network working group for tubular disorders","volume":"99","author":"Konrad","year":"2021","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2023.05.001","article-title":"Exogenous\" 5 alpha reductase deficiency: a case report","volume":"178","author":"Levy","year":"2023","journal-title":"Urology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J. Am. Acad. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1210\/endo-94-6-1628","article-title":"Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism","volume":"94","author":"Menard","year":"1974","journal-title":"Endocrinology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00045391-199901000-00009","article-title":"Calcium-channel blocker withdrawal in a pregnant woman","volume":"6","author":"Mertl","year":"1999","journal-title":"Am. J. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbagrm.2014.05.020","article-title":"Androgens and mammalian male reproductive tract development","volume":"1849","author":"Murashima","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur. Heart J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.2174\/1381612825666190215100502","article-title":"The mechanisms of actions of aldosterone and its antagonists in cardiovascular disease","volume":"24","author":"Pantelidis","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"B31","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrcardio.2015.172","article-title":"Use of medication for cardiovascular disease during pregnancy","volume":"12","author":"Pieper","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jum.16080","article-title":"The development of normal fetal external genitalia throughout gestation","volume":"42","author":"Pinson","year":"2023","journal-title":"J. Ultrasound Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/1871530322666220509051746","article-title":"Long-lasting effects of spironolactone after its withdrawal in patients with hyperandrogenic skin disorders","volume":"23","author":"Sabbadin","year":"2023","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"B35","first-page":"P3","article-title":"Ambiguous genitalia in a newborn with spironolactone exposure","author":"Shah","year":"2011"},{"key":"B36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvad165","article-title":"Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis","volume":"120","author":"Tian","year":"2024","journal-title":"Cardiovasc Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sapharm.2023.10.003","article-title":"Dispensing error rates in pharmacy: a systematic review and meta-analysis","volume":"20","author":"Um","year":"2024","journal-title":"Res. Soc. Adm. Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"bvac085","DOI":"10.1210\/jendso\/bvac085","article-title":"A case of a pregnant woman with primary aldosteronism and superimposed preeclampsia treated with esaxerenone","volume":"6","author":"Yamashita","year":"2022","journal-title":"J. Endocr. Soc."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1404251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:37:03Z","timestamp":1721882223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1404251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":39,"alternative-id":["10.3389\/fphar.2024.1404251"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1404251","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"article-number":"1404251"}}